Join us from 10 - 11 a.m. EST Thursday, November 17, for a complimentary webinar as our team shares their experience with selecting the right study design to address diverse evidence needs.
Real-world data on effectiveness, safety, and other outcomes are increasingly being demanded by multiple stakeholders. Data can be obtained using secondary data sources (electronic medical records, claims/administrative data, existing registries) or through primary de novo data collection.
Biosimilar agents are similar but non-identical versions of existing biological drugs and may be authorized for use once the patent on the reference product has expired. Based on a recent market forecast of IMS, biosimilars are forecasted to deliver total savings of as much as $110 billion to health systems across Europe and the U.S. through 2020.
Although much of the gerontological research in dermatology has focused on the signs of aging, there is a paucity of quantitative data that describes the psychosocial impact of aging. The results of “Self-Perception of Aging: Results from a Global Survey Assessing the Psychological Impact of Facial Aging,” presented at the ISPOR 21st Annual International Meeting in May, describe the impact of facial lines in diverse adult populations across gender and varying racial/ethnic groups.
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, conducted May 21-25, 2-16, in Washington, DC, industry professionals convened to delve into the topic “Value, Affordability, and Patient Centeredness: Can We Have it All?” UBC’s Value Demonstration experts joined the conversation with five abstracts highlighting some of their recentresearch.
UBC experts will be available at the 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) to discuss our tailored real-world evidence generation solutions. Stop by exhibit #12.
There is increasing demand from payers to gather evidence on the safety of medications used in the general population post-commercialization. Conducting a literature review involving critical appraisal is essential to better understand the research topic and assess the validity of the research findings. UBC can conduct literature reviews and other real-world evidence generation studies for your product.
Stop by booth 1206/1208 at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th annual meeting May 16 – 20 in Philadelphia to meet our scientific staff. Members of our Value Demonstration and Database Analytics Automation teams will be available throughout the conference to meet customers and talk about our real-world evidence solutions.
Evidentiary requirements in support of market access and reimbursement span the entire drug development lifecycle. A critical evidence gathering approach includes one or more reviews of literature to leverage published data on epidemiological outcomes, effectiveness, safety, burden and cost of illness, and health care utilization and care processes. These four key considerations will drive successful literature reviews.